HEALTHCARE (XLV)

Defensive sectors like consumer staples, healthcare, real estate, and utilities tend to perform well during market downturns and heightened volatility.

Amgen's shares fell 2.4% after-hours trading due to a mixed earnings release. MariTide, the company's weight loss drug, is in Phase II FDA trials.

The tech-led sell-off expanded and accelerated to close the week; more volatility may be the norm for the rest of the summer, which may force the Fed to move

The healthcare sector, represented by the XLV ETF, has seen a resurgence, breaking out of a multi-year consolidation phase and surging almost 3% in July.

Novartis released its Q2 financial results. It beat expectations on EPS and revenue. However, shares fell, possibly due to bad news on one upcoming drug.

Communications, technology, and healthcare are the three hottest sectors for growth, but not all stocks will rise with the tides.

Hims & Hers stock could give investors the best of both stability and double-digit upside through EPS projections and price targets, especially after 1Q24

CVS stock is making its way above Walgreens as a potential watchlist addition. Fundamentals and price targets see the stock making a comeback this year.

Investors now have an inside look at what one of Wall Street's biggest names is doing with its money. Corporations and clients all see new highs in stocks

Three stocks stand out as the most attractive dividend propositions, particularly now that savings yields may drop as a result of the Fed's rate cuts

Novo Nordisk and Nvidia have teamed up to develop supercomputers, aiming to accelerate drug discovery development using advanced AI technologies.

Driving a bargain of a short squeeze play, Bluebird Bio stock could soon announce what every investor is hoping to hear, here's what management could do

Bluebird Bio stock could be on the verge of a 400% pop on earnings, management has set the writing on the wall for institutional buying to trickle in

The S&P 500 hits new highs as 10 of the 11 S&P sectors report positive Q4 earnings surprises. The tech and energy sectors are among the earnings leaders.

Sectors including financials, healthcare, utilities and energy outperform as interest rates remain high, but some of those industries face challenges in 2024.

The healthcare sector could see a sudden inflow of investment dollars, and Eli Lilly quickly becomes a favorite name in the space as markets and analysts bid up

The healthcare sector is set to attract a new inflow of investment dollars, as seen in business activity and employment. Pfizer is the clear sector favorite

2024 holds promise for healthcare stocks, with Humana, Elevance, and others expected to boost earnings, as analysts say many industry pressures have been removed.

CVS plans to close dozens of Target pharmacies starting in February. Amid retail pharmacy challenges, CVS is shifting toward the managed-care industry.

The healthcare sector is one of the prime suspects to attract safety-seeking investors in the coming market shift. Within it, THIS stock can prove a winner

AstraZeneca's stock rose 8.95% in the past month on a bullish outlook, driven by growing sales of cancer and diabetes drugs and a strategic acquisition

HCA Healthcare rebounds amid concerns about weight-loss drugs' impact. The healthcare giant's revenue growth hints at resilience despite sector challenges.

Is 2024 the year defensive stocks rotate into leadership? As the year gets underway, defensives such as healthcare, energy, utilities and consumer staples lead.

Jobs are flowing to the healthcare space, and investment dollars are finding a home in stocks like Align Technology, even the CEO thought it to be the best

Pfizer's tumultuous 2023 included a 41.84% stock plunge as revenue from Covid drugs fell. Disappointing 2024 guidance resulted in analysts slashing targets.